Companies
MedChemExpress LLC (MCE)
Products
MedChemExpress - Model DMHCA - ...

MedChemExpress - Model DMHCA -79066-03-8

DMHCA, a potent and selective LXR agonist, specifically activates the cholesterol efflux arm of the LXR pathway without stimulating triglyceride synthesis. DMHCA has anti-inflammatory effects?and can be used for the research of cholesterol homeostasis diabetes[1].

DMHCA

MCE China：DMHCA

Brand：MedChemExpress (MCE)

Cat. No.HY-129098

CAS：79066-03-8

Purity：99.80%

Storage：Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month

Shipping：Room temperature in continental US; may vary elsewhere.

Description：DMHCA, a potent and selective LXR agonist, specifically activates the cholesterol efflux arm of the LXR pathway without stimulating triglyceride synthesis. DMHCA has anti-inflammatory effects?and can be used for the research of cholesterol homeostasis diabetes.

In Vitro：In ex vivo treatment of diabetic CD34+?cells, DMHCA (10 μM; 16-18 hours) restores the fluidity of the membranes to baseline nondiabetic levels[1].DMHCA restores the levels of BM-derived TNF-α and IL-3 to baseline and significantly reduces CCL-2 production by >50% in the BM supernatants and the systemic circulation compares to the control mice. DMHCA also increases the number of CACs in the BM and peripheral circulation and upregulates the egression of vascular reparative cells into the peripheral circulation[1].In the PAGA analysis, DMHCA treatment enhances the overall production and robustness of erythrocyte progenitors. DMHCA enhances flux down the erythrocyte progenitor lineage. It also DMHCA increase in erythrocyte progenitor density in BM cells. DMHCA not only expands the proportion of erythrocyte progenitors but also increases the expression of the hemoglobin beta adult chain (HBB-BT)[1].

In Vivo：DMHCA (oral administration; 6 months; chow 8mg/kg body weight /day) restores cholesterol homeostasis in diabetic retina. It significantly increases endogenous LXR ligands, desmosterol, and total oxysterols in the diabetic retina[1].

IC50 & Target：IC50: LXR[1] Cellular Effect Cell Line Type Value Description References

References：

[1]. Cristiano P Vieira, et al. Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes. JCI Insight. 2020 Jul 9;5(13):e137230. [Content Brief]

Brand introduction:
•   MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world；
•   More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas；
•   The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects；
•   Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services；
•   It has a professional experimental center and strict quality control and verification system；
•   Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products；
•   The biological activity of the products has been verified by the experiments of customers in various countries；
•   A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers；
•   Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world；
•   It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。

MedChemExpress - Model DMHCA -79066-03-8

MCE products for research use only. We do not sell...

DMHCA